Trial Profile

Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofarabine (Primary) ; Amsacrine; Cytarabine; Idarubicin
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use

31 Aug 2024 This trial has been completed in the Belgium (Global end date: 2023-09-28) according to European Clinical Trials Database record.
15 Dec 2023 This trial has been completed in the Netherlands (Global end date: 28 Sep 2023).
07 Jul 2012 Planned number of patients changed from 800 to 880, actual initiation date (25 Jan 2010) and additional trial location (Belgium) added as reported by European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com